株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Indian Immunologicals Limitedの製品パイプライン分析

Indian Immunologicals Limited - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 317362
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Indian Immunologicals Limitedの製品パイプライン分析 Indian Immunologicals Limited - Product Pipeline Review - 2016
出版日: 2016年02月29日 ページ情報: 英文 29 Pages
概要

Indian Immunologicals Limitedはインドに本社をおくファーマシューティカル企業で、小児用ワクチンおよびヒト狂犬病ワクチンの研究開発、製造、輸出を行っています。アニマルヘルス、ヒューマンヘルス、家畜生産性の向上サービス部門があり、国際的なビジネスを展開しています。

当レポートでは、Indian Immunologicals Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Indian Immunologicals Limitedの基本情報

  • Indian Immunologicals Limitedの概要
  • 主要情報
  • 企業情報

Indian Immunologicals Limited:R&Dの概要

  • 主な治療範囲

Indian Immunologicals Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Indian Immunologicals Limited:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床試験段階の製品/併用療法モダリティ
  • 開発段階が不明の製品
    • 開発段階が不明の製品/併用療法モダリティ

Indian Immunologicals Limited:薬剤プロファイル

  • chikungunya vaccine
  • DPT-H-HiB Vaccine
  • haemophilus influenzae vaccine type B
  • human papilloma virus vaccine types 16 and 18
  • alphavirus vaccine
  • flavivirus vaccine
  • Japanese encephalitis vaccine
  • picornavirus vaccine
  • vaccine for cervical cancer
  • Vaccine for Undisclosed Indication

Indian Immunologicals Limited:パイプライン分析

  • 投与経路別
  • 分子タイプ別

Indian Immunologicals Limited:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07972CDB

Summary

Global Markets Direct's, 'Indian Immunologicals Limited - Product Pipeline Review - 2016', provides an overview of the Indian Immunologicals Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Indian Immunologicals Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Indian Immunologicals Limited
  • The report provides overview of Indian Immunologicals Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Indian Immunologicals Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Indian Immunologicals Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Indian Immunologicals Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Indian Immunologicals Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Indian Immunologicals Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Indian Immunologicals Limited Snapshot
    • Indian Immunologicals Limited Overview
    • Key Information
    • Key Facts
  • Indian Immunologicals Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Indian Immunologicals Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Indian Immunologicals Limited - Pipeline Products Glance
    • Indian Immunologicals Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Indian Immunologicals Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Indian Immunologicals Limited - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Indian Immunologicals Limited - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • chikungunya vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus [serotypes 16, 18] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Japanese encephalitis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Alphavirus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • flavivirus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • picornavirus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Indian Immunologicals Limited - Pipeline Analysis
    • Indian Immunologicals Limited - Pipeline Products by Target
    • Indian Immunologicals Limited - Pipeline Products by Route of Administration
    • Indian Immunologicals Limited - Pipeline Products by Molecule Type
  • Indian Immunologicals Limited - Recent Pipeline Updates
  • Indian Immunologicals Limited - Dormant Projects
  • Indian Immunologicals Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Indian Immunologicals Limited, Key Information
  • Indian Immunologicals Limited, Key Facts
  • Indian Immunologicals Limited - Pipeline by Indication, 2016
  • Indian Immunologicals Limited - Pipeline by Stage of Development, 2016
  • Indian Immunologicals Limited - Monotherapy Products in Pipeline, 2016
  • Indian Immunologicals Limited - Combination Treatment Modalities in Pipeline, 2016
  • Indian Immunologicals Limited - Phase I, 2016
  • Indian Immunologicals Limited - Preclinical, 2016
  • Indian Immunologicals Limited - Unknown, 2016
  • Indian Immunologicals Limited - Pipeline by Target, 2016
  • Indian Immunologicals Limited - Pipeline by Route of Administration, 2016
  • Indian Immunologicals Limited - Pipeline by Molecule Type, 2016
  • Indian Immunologicals Limited - Recent Pipeline Updates, 2016
  • Indian Immunologicals Limited - Dormant Developmental Projects,2016
  • Indian Immunologicals Limited, Other Locations

List of Figures

  • Indian Immunologicals Limited - Pipeline by Top 10 Indication, 2016
  • Indian Immunologicals Limited - Pipeline by Stage of Development, 2016
  • Indian Immunologicals Limited - Monotherapy Products in Pipeline, 2016
  • Indian Immunologicals Limited - Pipeline by Route of Administration, 2016
  • Indian Immunologicals Limited - Pipeline by Molecule Type, 2016
Back to Top